# US 2026/0266822 A1 · Biomarkers for lung adenocarcinoma (luad), and method for treating luad

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0266822 A1
- Document ID: US20260266822A1
- Status: Published application
- Kind: A1
- Application number: 19/075,628
- Filed: 2025-03-10
- Published: 2026-09-10
- Earliest claimed: 2025-03-10
- Assignees: Taipei Veterans General Hospital
- Applicants: Taipei Veterans General Hospital
- Inventors: Mong-Lien WANG; Shih-Hwa CHIOU; Chih-Ying CHEN; Ping-Hsing TSAI; Lo-Jei CHING; Ming-Long TSAI; Yuh-Min CHEN; Yung-Hung LUO; Po-Kuei HSU
- Web page: https://patentgrep.com/patent/US20260266822A1

## CPC

- G01N 33/5752: of the lungs
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61P 35/00: Antineoplastic agents
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for predicting clinical outcomes of a lung cancer patient, such as LUAD, particularly LUAD with low expression of NKX2-1. Also provided includes a method for treating lung adenocarcinoma (LUAD) in a patient, comprising administering to said patient an inhibitor of CXCR2 at a therapeutically effective amount. The present invention provides a strategy of treatment to suppress tumorigenesis and improve the survival outcome of LUAD patients with NKX2-1-low malignant tumors through targeting the NKX2-1/CXC chemokine signaling.

## Claims

### Claim 1

A method for predicting clinical outcomes of a lung cancer patient, comprising providing a cancer cell sample of the patient, and detecting the expression level of NKX2-1 in the sample, wherein the clinical outcome is predicted as poor if the expression of NKX2-1 is low.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lung cancer is lung adenocarcinoma (LUAD).

### Claim 3

A method for treating lung adenocarcinoma (LUAD) in a patient, comprising administering to said patient an inhibitor of CXCR2 at a therapeutically effective amount.

### Claim 4 (depends on 3)

The method of claim 3, wherein the LUAD is a cancer with low expression of NKX2-1.

### Claim 5 (depends on 3)

The method of claim 3, wherein the inhibitor of CXCR2 is CXCL1, CXCL2, or CXCL5.

### Claim 6 (depends on 3)

The method of claim 3, wherein the inhibitor of CXCR2 is a CXCR2 antagonist, which comprises SB225002, MK-7123, Cpd 19, or AZD5069.
